Dr. Parsons has provided similar insights into the mechanisms through which endocannabinoids modulate the rewarding effects of opiates, alcohol, and cocaine, and he is presently extending his
evaluations of this stage of the addiction cycle to include
animal models of commonly occurring genetic polymorphisms that are associated with problematic
drug use and dependence in humans.
Having a strong R&D department with great experience and expertise in
drug development,
animal model and assay development and preclinical efficacy
evaluation, the contribution of Biomedcode has been greatly valued by our partners, as documented by our participation in several collaborative research projects.